N/A
Completed N=63
Changes in Serum Fibroblast Growth Factor 21 (FGF21) Levels Correlated With Exercise
Source: ClinicalTrials.gov NCT01512368 ↗Enrolled (actual)
63
Serious AEs
0.0%
Results posted
Mar 2012
Primary outcomePrimary: Change From Baseline Fibroblast Growth Factor 21 (FGF21) Acutely and at Two Weeks — 276.8; 460.8 ng/L — p=<0.001
Summary
We evaluated the effect of two weeks of intensive supervised physical activity in serum fibroblast growth factor 21 (FGF21) levels.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline Fibroblast Growth Factor 21 (FGF21) Acutely and at Two Weeks |
276.8; 460.8 | <0.001 sig |
| SECONDARY Change From Baseline Free Fatty Acids (FFAs) Acutely and at Two Weeks |
0.36; 0.54 | — |
| SECONDARY Change From Baseline Epinephrine Acutely and at Two Weeks |
9.2; 15.5 | — |
| SECONDARY Change From Baseline Leptin Acutely and at Two Weeks |
13.1; 12.4 | — |
| SECONDARY Change From Baseline Total Adiponectin Acutely and at Two Weeks |
10.1; 10.5 | — |
| SECONDARY Change From Baseline Fasting Glucose Acutely and at Two Weeks |
86.0; 86.3 | — |
Eligibility Criteria
Inclusion Criteria
- Women
- Aged 18 to 35 years old,
- Body mass index (BMI) <30 kg/m2
- Without contraindication for exercising
Exclusion Criteria
- Metabolic syndrome
- Diabetes
- Dyslipidemia
- Hypertension
- Asthma
- Thyroid disease
- Treated with fibrates, beta agonists or blockers
- History or current arrhythmias, murmurs, cardiomegaly, or treatment for cardiovascular diseases -
- Contraindications for exercise testing were also considered as exclusion criteria (see references)
Data sourced from ClinicalTrials.gov (NCT01512368). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.